

CD47 | SIRP α

SUMMIT

Targeting The Leading "Don't Eat Me" Signal

July 9th-10th, 2020 | Boston, MA

Conference Day 1, Thursday, July 9th.

8:00 Registration, Breakfast & Networking

9:00 Chair's Opening Remarks & Setting the Scene

- A look at the day ahead - what will be the key takeaways we should achieve by the end of this summit?
- How far have we come in the CD47|SIRP α space since last April?

Kipp Weiskopf, Whitehead Fellow, [Whitehead Institute](#)

9:10 Keynote Presentation: **Fundamental Biology of the CD47|SIRP α Checkpoint**

Timo Van Den Berg, Professor of Immunotherapy, Head Department of Blood Cell Research, [Sanquin Research](#), [Amsterdam University Medical Center](#)

9:35 Presentation: **A Novel MOA-reflective Bioassay for Quantifying Potency of Therapeutics Targeting the SIRP α | CD47 Signaling Axis**

- Assay principle and relevance to MOA of SIRP α /CD47 signaling in macrophages
- Assay characterization and optimization/development history
- Suitability of the assay for potency determination and characterization of anti-SIRP α /anti-CD47
- Therapeutics

Jane Lamerdin, Director, R&D, [Eurofins DiscoverX](#)

10:00 Panel Discussion and Open Q&A: **What Impact is our Current Level of Understanding of the CD47|SIRP α Checkpoint Having on the Industry?**

- What knowledge do we need to further the development of CD47|SIRP α targeted therapies?
- What are the specific hurdles within research that prevents information about the CD47|SIRP α being discovered?
- Do we understand sufficiently which immune functions are controlled by CD47-SIRP α and how?
- As we move further into human trials, what are we expecting to learn about the fundamental biology of CD47/SIRPa?

- **Dan Pereira**, CSO, **Arch Oncology**
- **Michal Caspi Tal**, Instructor & Team Lead, **Stanford University**
- **Anthony Schwartz**, CEO, **Morphix**
- **Timo Van Den Berg**, Professor of Immunotherapy, Head Department of Blood Cell Research, **Sanquin Research, Amsterdam University Medical Center**

10:40

Morning Refreshments & Networking

11:20 Presentation: **What Do We Know About the Fundamental Biology Behind Alternative SIRP Homologs and an Overview of OSE Immunotherapeutics' Approach**

Nicolas Poirier, CSO, **OSE Immunotherapeutics**

11:45 Presentation: **How Do Macrophages Work In Relation To CD47|SIRP α ?**

- We learn more about the fundamental biology behind macrophages and how they interact with CD47.
- Why Macrophages rather than dendritic/myeloid cells?
- What is the role of macrophage polarity as it pertains to promoting phagocytosis following SIRPa/CD47 blockade?

Stephanie Dougan, Assistant Professor, **Dana-Farber Cancer Institute**

12:10 Panel Discussion and Open Q&A: **What Does "Eat Me" Mechanistically Mean for Macrophages In Relation To CD47|SIRP α ?**

- How do we activate and how do we increase macrophage activity?
- What are the different types of macrophages, does the targeted therapy approach need to change depending on the type of macrophage?
- Can CD47/SIRPa blockade single handedly influence what macrophages do with the tumor antigens after they are 'eaten'?

- What other signals/pathways in macrophages need to be engaged?
- How do we measure/confirm macrophage phagocytosis in a clinical trial setting?

- **Siddhartha Mitra**, Assistant Professor, **University of Colorado**
- **Sergio Trombetta**, Senior Principal Scientist, Cancer Immunology & Immune Modulation, **Boehringer Ingelheim**
- **Stephanie Dougan**, Assistant Professor, **Dana-Farber Cancer Institute**
- **Yoji Murata**, Associate Professor, Dean of the Graduate School of Medicine, **Kobe University**

12:50

Lunch & Networking

Combinations in Action

1:50 Presentation: **QPCTL - A Druggable Modifier of the CD47/SIRP Therapeutic Axis**

Sebastian Nijman, Founder & Managing Director, **Scenic Biotech**

2:15 Panel Discussion and Open Q&A: **Chemotherapy, T-cell Immunotherapy and Radiotherapy - Where do these Fit in Combination with CD47|SIRP α ?**

- What do we know so far about combining these targets with CD47|SIRP α both preclinically and clinically?
- How effectively does radiotherapy work alongside CD47|SIRP α ?
- What are the risks of combining these immuno-oncology targets?
- What are the potential impacts of immunogenic vs non-immunogenic cell killing on CD47|Sirpa compounds, does one route work better than the other?
- How predictive/how useful are preclinical models in this space?

- **Siddhartha Mitra**, Assistant Professor, **University of Colorado**
- **André Veillette**, Professor, Department of Medicine, **University of Montreal**
- **Timothy Zheng**, Executive Director, Immune Modulation, **Boehringer Ingelheim**

CD47|SIRP α in the Clinic

2:50 Presentation: **Tackling Solid Cancers using a Bispecific Antibody Approach - Light Chain Bioscience**

- A look at the advantages of targeting CD47 with a bispecific antibody approach.
- We hear about Mesothelin as a target for solid cancers.
- An insight into preclinical data for the CD47 x Mesothelin bispecific antibody.

Limin Shang, Pharmacology Director, **LightChain Bioscience**

3:15

Afternoon Refreshments & Networking

4:00 Presentation: **ALX148: Designed For Safety To Maximize Efficacy.**

- Design of ALX148 and mechanistic insights into its safety/efficacy profile
- Overview of clinical results from the ALX148 program

Jaume Pons, President & CEO, **ALX Oncology**

4:25 Presentation: **TJC4 – A Differentiated CD47 Antibody in Clinical Development**

- An insight into how I-Mab Biopharma discovered an antibody with differentiated properties to reduce RBC binding.
- We learn about I-Mab Biopharma's attempt to understand the mechanisms underlying these differentiated properties.

Claire Xu, Head of US Site, **I-Mab Biopharma**

4:50 Panel Discussion and Open Q&A: **What are the Predictive Biomarkers Arising when Targeting CD47 | SIRP α Pathways?**

- What are the best biomarker strategies to validate how clinical trials are going?
- SIRP α /CD47 tumoral expression: is there any correlation with clinical efficacy?
- Macrophage/T-cell infiltrates: is there any correlation with clinical efficacy?
- What other biomarkers should be considered in regards to CD47 | SIRP α drugs?
- What biomarkers are biotech companies using to track macrophages in clinic?

Moderated by: **Nicolas Poirier**, CSO, **OSE Immunotherapeutics**

- **Claire Xu**, Head of US Site, **I-Mab Biopharma**
- **André Veillette**, Professor, Department of Medicine, **University of Montreal**
- **Spencer Liang**, Senior Director, Head of Immuno-Oncology, **Alector**
- **Limin Shang**, Pharmacology Director, **LightChain Bioscience**

5:30 Close of Day 1

Conference Day 2 - Friday, July 10th.

9:00 Chair's Opening Remarks & Setting the Scene

- What have we learnt so far at CD47|SIRP α 2020?
- What can we expect from today?

Siddhartha Mitra, Assistant Professor, **University of Colorado**

9:10 Presentation: An Insight into Trillium Therapeutics' Progress and What's To Come.

Yaping Shou, Chief Medical Officer, **Trillium Therapeutics**

9.35 Presentation: Genetic Variations in SIRPa Impact CD47 Interactions.

Michal Caspi Tal, Instructor & Team Lead, **Stanford University**

Building Clinical Best Practice

10:00 Panel Discussion and Open Q&A: How Can we Manage Toxicity and Improve Clinical Practice?

- What toxicities have been identified during preclinical & clinical trials?
- Are there specific causes for toxicity and how can we negate these?
- Are pre-clinical non-human samples posing problems for future clinical trials?
- The RACE For Children Act comes into effect in August 2020, how will this affect clinical trials?
- How else can we build best practices in clinic?

- **Tabitha Cooney**, Pediatric Neuro-Oncologist, **Dana Farber Cancer Institute**
- **Michael Dougan**, Assistant Professor, Medicine, **Harvard Medical School**
- **Daniel Masylar**, VP of Clinical Development for Oncology, **Alector**

10:40

Morning Refreshments & Networking

Additional Pathways - What Else Is In The Pipeline?

11:30 Presentation: **CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade to Bridge Innate and Adaptive Immunity.**

Taylor Schreiber, CEO, [Shattuck Labs](#)

11:55 Presentation: **AO-176, A Highly Differentiated Clinical Stage Anti-CD47 Antibody.**

- We learn how Arch Oncology is working to bridge innate and adaptive anti-tumor immunity through development of AO-176.
- An insight into the clinical trials for AO-176 and what's to come.

Dan Pereira, CSO, [Arch Oncology](#)

12:20 Presentation: **An Insight Into Alector's Novel Approach to Drive Anti-Tumor Immunity.**

Andrew Picentic, Staff Scientist & Program Lead, [Alector](#)

12:45

Lunch & Networking

What's On The Horizon?

2:15 Panel Discussion and Open Q&A: **Reflection and Progression - Where are We and What's Next for CD47|SIRP α ?**

- What challenges have we faced and how can we overcome these?
- Where do we expect to see the most growth in the next year?
- Should enhancing mediated-macrophage phagocytosis be a focus going forward?
- How is the future work on emerging "don't eat me" signals going to benefit from our work with CD47/SIRP α ?

- What have been our biggest takeaways from the CD47/SIRPa 2020 Summit

- **Timothy Zheng**, Executive Director, Immune Modulation, **Boehringer Ingelheim**
- **Taylor Schreiber**, CEO, **Shattuck Labs**
- **Sebastian Nijman**, Founder & Managing Director, **Scenic Biotech**

2:55 Chairs Closing Remarks

- What have been the key learnings from CD47|SIRP α 2020?

Siddhartha Mitra, Assistant Professor, **University of Colorado**

3:00 Close of CD47|SIRPa 2020